Effects of cytotoxic chemotherapeutic agents on split-dose repair in intestinal crypt cells.
OBJECTIVE
Many cancer chemotherapeutic agents interact with radiation to enhance the amount of radiation damage observed in both tumor and normal tissues. It is important to predict this interaction and to determine the effect of drug on sublethal damage repair. To evaluate for effects in rapid renewing normal tissues, the intestinal crypt cell in vivo assay is an excellent one to employ. These studies investigate the effect of eleven cancer chemotherapeutic drugs on split-dose repair in the intestinal crypt cell of the mouse.


METHODS
LAF1 male mice, age 10-12 weeks, were exposed to whole-body irradiation with orthovoltage x-rays delivered as a single dose or as equally divided doses delivered with intervals between the two exposures of 2 to 24 h. In the experimental group, the cancer chemotherapeutic agent was administered intraperitoneally 2 h before the first radiation dose. At 3.6 days after the second irradiation, the mice were sacrificed; the jejunum was removed, fixed, and sectioned for light microscopy. The number of regenerating crypts were counted and corrected to represent the number of surviving cells per circumference.


RESULTS
Of the eleven drugs tested, only carmustine eliminated split-dose repair. Cisplatin delayed repair, and methotrexate caused marked synchronization obliterating the observation of split-dose repair.


CONCLUSIONS
Most cytotoxic chemotherapeutic agents do not inhibit sublethal damage repair in intestinal crypt cells when given 2 h before the first radiation exposure. Absence of the initial increase in survival seen with split-dose radiation is noted with carmustine and high-dose methotrexate.
Phillips
T L
TL
Department of Radiation Oncology, University of California-San Francisco, 94143, USA.
Ross
G Y
GY
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D007263:Infusions, Parenteral; D007583:Jejunum / Q000187:drug effects* / Q000528:radiation effects*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D014916:Whole-Body Irradiation; D014945:Wound Healing / Q000187:drug effects*
D000970:Antineoplastic Agents